PTC Therapeutics - PTCT Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Reduce
Consensus Price Target: $33.53
Forecasted Upside: 31.55%
Number of Analysts: 13
Breakdown:
5 Sell Ratings
5 Hold Ratings
3 Buy Ratings
0 Strong Buy Ratings

^$25.49 As of 04/25/2024 01:00 AM ET

▲ +0.28 (1.11%)

1 month | 3 months | 12 months

Get New PTC Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for PTCT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PTCT

^$33.53

▲ +31.55% Upside Potential

This price target is based on 13 analysts offering 12 month price targets for PTC Therapeutics in the last 3 months. The average price target is $33.53, with a high forecast of $55.00 and a low forecast of $17.00. The average price target represents a 31.55% upside from the last price of $25.49.

Current Consensus is Reduce

The current consensus among 13 contributing investment analysts is to reduce stock in PTC Therapeutics. This Reduce consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
3 buy ratings
5 hold ratings
5 sell ratings

Ratings as of

11/1/2022

0 strong buy ratings
3 buy ratings
5 hold ratings
5 sell ratings

Ratings as of

1/30/2023

0 strong buy ratings
3 buy ratings
5 hold ratings
5 sell ratings

Ratings as of

4/30/2023

0 strong buy ratings
3 buy ratings
5 hold ratings
5 sell ratings

Ratings as of

7/29/2023

0 strong buy ratings
3 buy ratings
5 hold ratings
5 sell ratings

Ratings as of

10/27/2023

0 strong buy ratings
3 buy ratings
5 hold ratings
5 sell ratings

Ratings as of

1/25/2024

0 strong buy ratings
3 buy ratings
5 hold ratings
5 sell ratings

Ratings as of

3/25/2024

0 strong buy ratings
3 buy ratings
5 hold ratings
5 sell ratings

Ratings as of

4/24/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/12/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$45.00	Low
3/20/2024	Jefferies Financial Group	Boost Target	Buy ➝ Buy	$33.00 ➝ $35.00	Low
3/1/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$45.00	Low
3/1/2024	Royal Bank of Canada	Boost Target	Sector Perform ➝ Sector Perform	$22.00 ➝ $28.00	Low
3/1/2024	TD Cowen	Lower Target	Market Perform ➝ Market Perform	$32.00 ➝ $30.00	Low
1/26/2024	Cantor Fitzgerald	Lower Target	Overweight ➝ Overweight	$51.00 ➝ $45.00	Low
1/26/2024	Royal Bank of Canada	Lower Target	Sector Perform ➝ Sector Perform	$27.00 ➝ $22.00	Low
12/19/2023	Morgan Stanley	Downgrade	Equal Weight ➝ Underweight	$28.00	Low
12/18/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$51.00	Low
12/8/2023	Wells Fargo & Company	Initiated Coverage	Overweight	$37.00	Low
11/20/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$51.00	Low
10/27/2023	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$31.00 ➝ $28.00	Low
10/27/2023	Barclays	Lower Target	Equal Weight ➝ Equal Weight	$26.00 ➝ $25.00	Low
10/27/2023	Citigroup	Downgrade	Neutral ➝ Sell	$29.00 ➝ $17.00	Low
10/5/2023	Truist Financial	Downgrade	Buy ➝ Hold	$45.00 ➝ $25.00	Low
9/19/2023	Bank of America	Lower Target	Underperform ➝ Underperform	$43.00 ➝ $23.00	Low
9/18/2023	Truist Financial	Lower Target	Buy ➝ Buy	$60.00 ➝ $45.00	Low
9/18/2023	SVB Leerink	Lower Target		$44.00 ➝ $30.00	Low
9/18/2023	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$47.00 ➝ $31.00	Low
9/18/2023	The Goldman Sachs Group	Lower Target	Sell ➝ Sell	$35.00 ➝ $22.00	Low
9/18/2023	Royal Bank of Canada	Lower Target	Sector Perform ➝ Sector Perform	$49.00 ➝ $26.00	Low
9/18/2023	JPMorgan Chase & Co.	Lower Target		$70.00 ➝ $53.00	Low
9/18/2023	Barclays	Lower Target	Equal Weight ➝ Equal Weight	$44.00 ➝ $26.00	Low
9/18/2023	Citigroup	Downgrade	Buy ➝ Neutral	$55.00 ➝ $28.00	Low
9/15/2023	Raymond James	Downgrade	Outperform ➝ Underperform		Low
8/16/2023	Truist Financial	Reiterated Rating	Buy ➝ Buy	$65.00	Low
8/7/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$73.00	Low
8/4/2023	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$47.00	Low
8/4/2023	Barclays	Lower Target	Equal Weight ➝ Equal Weight	$48.00 ➝ $44.00	Low
8/4/2023	Raymond James	Lower Target	Outperform ➝ Outperform	$58.00 ➝ $55.00	Low
7/20/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$73.00	Low
7/20/2023	Royal Bank of Canada	Reiterated Rating	Sector Perform ➝ Sector Perform	$49.00	Low
7/20/2023	Credit Suisse Group	Reiterated Rating	Neutral ➝ Neutral	$50.00	Low
6/30/2023	Cantor Fitzgerald	Lower Target	Overweight	$75.00 ➝ $73.00	Low
5/24/2023	Credit Suisse Group	Lower Target		$55.00 ➝ $50.00	Low
5/24/2023	Citigroup	Lower Target		$70.00 ➝ $63.00	Low
5/24/2023	Barclays	Lower Target		$57.00 ➝ $48.00	Low
5/18/2023	VNET Group	Reiterated Rating	Maintains		Low
5/18/2023	Bank of America	Boost Target		$36.00 ➝ $43.00	Low
5/18/2023	Citigroup	Boost Target		$67.00 ➝ $70.00	Low
5/18/2023	Barclays	Boost Target		$47.00 ➝ $57.00	Low
5/17/2023	The Goldman Sachs Group	Boost Target		$35.00 ➝ $37.00	Low
5/8/2023	JPMorgan Chase & Co.	Boost Target		$57.00 ➝ $64.00	Low
4/28/2023	Credit Suisse Group	Boost Target		$48.00 ➝ $51.00	Low
4/28/2023	Citigroup	Boost Target		$61.00 ➝ $67.00	Low
4/18/2023	Truist Financial	Boost Target		$60.00 ➝ $65.00	Low
3/22/2023	William Blair	Reiterated Rating	Outperform		Low
3/17/2023	SVB Leerink	Reiterated Rating	Market Perform	$48.00	Low
3/17/2023	SVB Securities	Initiated Coverage	Market Perform	$48.00	Low
2/23/2023	Raymond James	Lower Target	Outperform	$60.00 ➝ $55.00	Low
2/22/2023	Royal Bank of Canada	Boost Target		$44.00 ➝ $51.00	Low
2/22/2023	Cantor Fitzgerald	Lower Target	Overweight	$68.00 ➝ $66.00	Low
2/22/2023	Credit Suisse Group	Reiterated Rating	Neutral	$48.00	Low
2/3/2023	Morgan Stanley	Boost Target	Equal Weight	$40.00 ➝ $50.00	Low
1/10/2023	Credit Suisse Group	Boost Target	Neutral	$47.00 ➝ $48.00	Low
12/14/2022	The Goldman Sachs Group	Initiated Coverage	Sell	$35.00	Low
11/1/2022	Cowen	Lower Target		$44.00	Low
11/1/2022	Barclays	Lower Target		$47.00	Low
10/28/2022	Royal Bank of Canada	Lower Target	Sector Perform	$60.00 ➝ $46.00	Low
10/28/2022	Morgan Stanley	Lower Target	Equal Weight	$54.00 ➝ $40.00	Low
10/28/2022	Credit Suisse Group	Lower Target	Neutral	$55.00 ➝ $47.00	Low
10/17/2022	Royal Bank of Canada	Boost Target	Sector Perform	$49.00 ➝ $60.00	Low
9/12/2022	Jefferies Financial Group	Initiated Coverage	Buy	$62.00	Low
9/9/2022	Morgan Stanley	Initiated Coverage	Equal Weight	$54.00	Low
9/1/2022	Citigroup	Initiated Coverage	Buy	$70.00	Low
8/11/2022	Raymond James	Boost Target	Outperform	$55.00 ➝ $60.00	Low
8/9/2022	Credit Suisse Group	Boost Target		$55.00	Low
7/22/2022	Credit Suisse Group	Boost Target		$52.00	Low
6/23/2022	Royal Bank of Canada	Boost Target	Sector Perform	$42.00 ➝ $46.00	Low
4/1/2022	Cantor Fitzgerald	Reiterated Rating	Overweight	$64.00 ➝ $63.00	N/A
2/23/2022	JPMorgan Chase & Co.	Boost Target	Overweight	$70.00 ➝ $76.00	High
2/23/2022	Barclays	Lower Target	Equal Weight	$40.00 ➝ $39.00	High
10/29/2021	Raymond James	Lower Target	Outperform	$70.00 ➝ $55.00	High
10/29/2021	Royal Bank of Canada	Lower Target	Sector Perform	$45.00 ➝ $42.00	Medium
10/29/2021	Credit Suisse Group	Lower Target	Neutral	$50.00 ➝ $48.00	High
10/18/2021	Bank of America	Downgrade	Neutral ➝ Underperform	$38.00	High
8/31/2021	UBS Group	Lower Target	Neutral	$55.00 ➝ $45.00	High
7/30/2021	Credit Suisse Group	Lower Target	Neutral	$54.00 ➝ $50.00	Low
6/3/2021	William Blair	Reiterated Rating	Buy		High
5/17/2021	Truist Financial	Lower Target	Buy	$75.00 ➝ $65.00	Low
4/26/2021	Credit Suisse Group	Initiated Coverage	Neutral	$54.00	High
3/29/2021	Royal Bank of Canada	Upgrade	Underperform ➝ Sector Perform	$47.00	Medium
2/26/2021	Cantor Fitzgerald	Lower Target	Overweight	$81.00 ➝ $75.00	High
2/12/2021	Bank of America	Downgrade	Buy ➝ Neutral		Low
1/5/2021	Smith Barney Citigroup	Upgrade	Neutral ➝ Buy		N/A
12/16/2020	Raymond James	Boost Target	Outperform	$63.00 ➝ $70.00	Medium
11/30/2020	Royal Bank of Canada	Downgrade	Sector Perform ➝ Underperform	$45.00	High
10/30/2020	Smith Barney Citigroup	Downgrade	Buy ➝ Neutral		Medium
10/30/2020	Cantor Fitzgerald	Lower Target	Overweight	$75.00 ➝ $67.00	High
10/28/2020	UBS Group	Initiated Coverage	Neutral	$55.00	Medium
10/7/2020	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$71.00	High
9/23/2020	Raymond James	Reiterated Rating	Buy		Medium
8/24/2020	Raymond James	Initiated Coverage	Outperform	$63.00	High
8/11/2020	Cantor Fitzgerald	Lower Target	Overweight	$85.00 ➝ $75.00	Low
8/10/2020	Bank of America	Lower Target	Buy	$60.00 ➝ $58.00	Medium
8/10/2020	Credit Suisse Group	Lower Target	Neutral	$53.00 ➝ $52.00	Low
7/20/2020	Cowen	Reiterated Rating	Hold	$50.00	High
7/20/2020	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$53.00	High
7/20/2020	SunTrust Banks	Boost Target	Buy	$75.00 ➝ $86.00	High
5/1/2020	SunTrust Banks	Lower Target	Buy	$78.00 ➝ $75.00	Medium
4/28/2020	William Blair	Reiterated Rating	Buy		Low
4/9/2020	Citigroup	Upgrade	Neutral ➝ Buy	$71.00 ➝ $67.00	High
4/8/2020	Cantor Fitzgerald	Lower Target	Overweight	$86.00 ➝ $85.00	Medium
4/8/2020	Royal Bank of Canada	Reiterated Rating	Hold	$45.00	High
3/4/2020	Barclays	Reiterated Rating	Hold	$51.00	High
3/3/2020	Cantor Fitzgerald	Reiterated Rating	Positive ➝ Overweight	$81.00 ➝ $86.00	High
3/2/2020	Cowen	Reiterated Rating	Hold		High
2/20/2020	Citigroup	Downgrade	Buy ➝ Neutral	$55.00 ➝ $71.00	High
2/20/2020	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$63.00 ➝ $60.00	High
2/6/2020	SunTrust Banks	Reiterated Rating	Buy	$78.00	Medium
2/6/2020	Cowen	Reiterated Rating	Hold		High
1/23/2020	Cantor Fitzgerald	Boost Target	Overweight	$60.00 ➝ $81.00	Low
1/15/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$60.00	Medium
12/5/2019	Royal Bank of Canada	Reiterated Rating	Outperform	$58.00	Medium
11/26/2019	William Blair	Reiterated Rating	Buy		Low
11/12/2019	SunTrust Banks	Initiated Coverage	Buy	$78.00	Low
10/31/2019	Credit Suisse Group	Reiterated Rating	Buy	$54.00	Low
10/30/2019	Cowen	Reiterated Rating	Hold		High
9/26/2019	Citigroup	Set Target	Buy	$62.00	High
9/24/2019	Royal Bank of Canada	Reiterated Rating	Buy		High
8/12/2019	Barclays	Reiterated Rating	Hold	$43.00	Low
5/13/2019	Bank of America	Upgrade	Neutral ➝ Buy	$43.00 ➝ $49.00	Low
5/8/2019	Cowen	Reiterated Rating	Hold		High
5/3/2019	Citigroup	Set Target	Buy	$59.00	Low
5/2/2019	Cowen	Reiterated Rating	Hold		High

(Data available from 4/25/2019 forward)

News Sentiment Rating

0.98 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

14 very positive mentions
5 positive mentions
2 negative mentions
2 very negative mentions

Mentions as of

9/28/2023

2 very positive mentions
13 positive mentions
3 negative mentions
3 very negative mentions

Mentions as of

10/28/2023

0 very positive mentions
3 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

11/27/2023

4 very positive mentions
5 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

12/27/2023

8 very positive mentions
10 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

1/26/2024

8 very positive mentions
5 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

2/25/2024

14 very positive mentions
16 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

3/26/2024

11 very positive mentions
8 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/25/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Negative

No negative mentions tracked during this time.

Positive

prnewswire.com
4 hours ago
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
prnewswire.com
4/23/2024
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
americanbankingnews.com
4/21/2024
Eric Pauwels Sells 787 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock
investing.com
4/20/2024
PTC Therapeutics CEO sells shares worth over $19k
americanbankingnews.com
4/18/2024
PTC Therapeutics (PTCT) Set to Announce Quarterly Earnings on Thursday

Very Positive

insidertrades.com
4/23/2024
Insider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Sells 3,361 Shares of Stock
americanbankingnews.com
4/23/2024
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Reduce" from Brokerages
marketbeat.com
4/23/2024
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Recommendation of "Reduce" by Brokerages
marketbeat.com
4/22/2024
Matthew B. Klein Sells 3,361 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock
marketbeat.com
4/21/2024
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by Knights of Columbus Asset Advisors LLC

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Today's Range

Now: $25.49

$24.00

$25.65

50 Day Range

MA: $28.11

$24.69

$31.95

52 Week Range

Now: $25.49

$17.53

$59.84

Volume

1,024,817 shs

Average Volume

961,586 shs

Market Capitalization

$1.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.67

Frequently Asked Questions

What sell-side analysts currently cover shares of PTC Therapeutics?: The following sell-side analysts have issued research reports on PTC Therapeutics in the last twelve months: Bank of America Co., Barclays PLC, Cantor Fitzgerald, Citigroup Inc., Credit Suisse Group AG, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Raymond James, Royal Bank of Canada, StockNews.com, SVB Leerink LLC, TD Cowen, The Goldman Sachs Group, Inc., Truist Financial Co., VNET Group, Inc., and Wells Fargo & Company.
View the latest analyst ratings for PTCT.
What is the current price target for PTC Therapeutics?: 15 Wall Street analysts have set twelve-month price targets for PTC Therapeutics in the last year. Their average twelve-month price target is $33.53, suggesting a possible upside of 31.6%. Raymond James has the highest price target set, predicting PTCT will reach $55.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $17.00 for PTC Therapeutics in the next year.
View the latest price targets for PTCT.
What is the current consensus analyst rating for PTC Therapeutics?: PTC Therapeutics currently has 5 sell ratings, 5 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for PTCT.
What other companies compete with PTC Therapeutics?: Other companies that are similar to PTC Therapeutics include Maravai LifeSciences, Galapagos, NewAmsterdam Pharma, Geron and Keros Therapeutics. Learn More about companies similar to PTC Therapeutics.
How do I contact PTC Therapeutics' investor relations team?: PTC Therapeutics' physical mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company's listed phone number is (908) 222-7000 and its investor relations email address is [email protected]. The official website for PTC Therapeutics is www.ptcbio.com. Learn More about contacing PTC Therapeutics investor relations.

PTC Therapeutics - PTCT Stock Price Target and Predictions

Analyst Price Target for PTCT

Current Consensus is Reduce

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.98 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of PTC Therapeutics?

What is the current price target for PTC Therapeutics?

What is the current consensus analyst rating for PTC Therapeutics?

What other companies compete with PTC Therapeutics?

How do I contact PTC Therapeutics' investor relations team?